Dow Down1.60% Nasdaq Down0.39%

Synergy Pharmaceuticals, Inc. (SGYP)

3.46 Up 0.02(0.58%) Feb 11, 4:00PM EST
ProfileGet Profile for:
Synergy Pharmaceuticals, Inc.
420 Lexington Avenue
Suite 2012
New York, NY 10170
United States - Map
Phone: 212-297-0020
Fax: 212-297-0019

Index Membership:N/A
Industry:Drug Manufacturers - Other
Full Time Employees:35

Business Summary 

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company is also developing SP-333, which is in Phase II clinical trials to treat opioid induced constipation, as well as in Phase Ib clinical trials to treat ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Synergy Pharmaceuticals, Inc.

Corporate Governance 
Synergy Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 3; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Gary S. Jacob Ph.D., 69
Chairman, Chief Exec. Officer and Pres
Dr. Kunwar Shailubhai Ph.D., M.B.A., 58
Chief Scientific Officer and Exec. VP
Dr. Patrick H. Griffin M.D., FACP, 61
Chief Medical Officer and Exec. VP
Mr. Gary L. Sender ,
Chief Financial Officer and Exec. VP
Gem Gokmen Hopkins ,
VP of Investor Relations and Corp. Communications
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders